Can you use Mammaprint to decide on chemotherapy in a young patient with positive sentinel nodes if no further axillary dissection is planned to see if there is more nodal involvement?

Mammoprint is the only genomic assay with level one evidence in node positive patients. Assuming that no axillary dissection to be done suggests ACOSOG Z-11 in a lumpectomy patient. Most would agree that taking more than one sentinel node decreases the risk of false negative assays so, in a patient like this it would have been preferable if more than one sentinel node was taken. Also, no info given on other prognostic variables to establish a clinical risk pattern of the primary. With those prov...